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INTRODUCTION
Over the past two decades, there has
been tremendous progress in molecular
genetics of heritable skin diseases, and
as many as 500 distinct human genes
are now known to harbor mutations in
these diseases (Feramisco et al., 2009).
The clinical implications of this pro-
gress are evident in the diagnosis and
management of these diseases. For
example, (a) identification of the spe-
cific mutations can be used for con-
firmation of diagnosis with prognostic
implications; (b) identification of muta-
tions has facilitated assessment of the
precise mode of inheritance, particu-
larly in cases with no previous family
history of the disease; and (c) identi-
fication of candidate genes and
mutations has formed the basis for
DNA-based prenatal testing and pre-
implantation genetic diagnosis in
families at risk for recurrence (Uitto,
2009). However, in spite of significant
progress in identification of the mole-
cular bases of heritable skin diseases,
there has been relatively little progress
until very recently in developing effec-
tive and specific treatments. This
synopsis will highlight some of the
milestones in progress towards treat-
ment and cure of heritable skin diseases,
primarily focusing on epidermolysis
bullosa (EB) as a paradigm of such
conditions, with emphasis on develop-
ment of gene-, protein-, and cell-based
molecular strategies just entering the
clinical arena (Uitto et al., 2012).
PRECLINICAL MODEL SYSTEMS
EB is a heterogeneous group of herita-
ble blistering disorders due to fragility
of the cutaneous basement membrane
zone (Bruckner-Tuderman and Has,
2012; Fine et al., 2008; Intong and
Murrell, 2012). The development of
molecular therapies for skin diseases
has been largely predicated upon de-
velopment of animal model systems,
particularly transgenic mice that reca-
pitulate their clinical, histopatho-
logical, and ultrastructural features
(Bruckner-Tuderman et al., 2010;
Natsuga et al., 2010). In the case of
EB, these include knockout mice with
targeted ablation of the corresponding
gene, such as those encoding type VII
collagen, type XVII collagen, or the
subunit polypeptides of laminin 332.
Also, identification of naturally occur-
ring spontaneous mutations in mice
and other vertebrates has been help-
ful for development of preclinical
approaches. In addition to trans-
genic animals, human xenograft trans-
plants onto immunocompromised mice
have provided useful model systems
(Siprashvili et al., 2010). Finally, novel
vertebrate model systems, such as
zebrafish, have been explored as
potential models for heritable skin
diseases (Li et al., 2011). Information
gleaned from the experiments utilizing
preclinical animal models has been
critical for the development of gene
therapy approaches for EB.
PROSPECTS OF GENE THERAPY
The first Milestone for applying gene
therapy for EB took place in 2005,
when cultured keratinocyte stem cells
with holoclone potential were cultured
from the skin of a patient with a
junctional form of EB (Mavilio et al.,
2006). This patient was shown to have
mutations in the LAMB3 gene, which
encodes the b3-subunit polypeptide of
laminin 332. The patient, a 36-year-old
man, had a form of non-Herlitz
junctional EB caused by compound
heterozygosity for a LAMB3 null muta-
tion and a missense mutation (E210K)
that, in addition to the amino acid
substitution, disrupts intron splicing.
Holoclone-forming cells were not
present in the blistering areas of skin,
most likely because the continuous
proliferative stimulus associated with
the chronic wound-healing process
had depleted the stem cell pool. How-
ever, biopsy from the palm area, which
blisters less, if at all, allowed a suffi-
cient number of holoclones to be
cultured. The cultured cells were trans-
duced with a Maloney leukemia vir-
us–derived retroviral vector expressing
the LAMB3 complementary DNA, and
these cells were then used to prepare
genetically corrected epidermal grafts
in culture (Figure 1). The grafts were
transplanted onto selected areas of the
patient’s legs, which were prepared for
acceptance of the graft by laser abla-
tion of the deficient epidermis. Engraft-
ment was shown to result in synthesis
and proper assembly of normal levels
of functional laminin 332, which clini-
cally resulted in development of ad-
herent epidermis that remained stable
and did not demonstrate blistering
(Mavilio et al., 2006). A published 3.5
year follow-up noted that on clinical
examination, no blisters were observed
in the transplanted area of skin, and the
regenerated skin was stable, normal
looking, and functionally resilient to
mechanical trauma (De Luca et al.,
2009). There was no evidence of
inflammation, and specific tests carried
out 3 and 6 months after the transplan-
tation procedure indicated the absence
of both humoral and T cell–mediated
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cytotoxic immune responses against
the transgene product. It should be
noted that one of the mutant alleles
contained a single point mutation
(E210K), which allowed residual
expression of some laminin 332. Thus,
the introduction of the complementary
DNA–derived laminin b3 polypeptide
was not recognized as a new protein by
the patient’s immune system, and no
evidence of rejection has been noted.
Although this study clearly provided
proof-of-principle of ex vivo keratino-
cyte therapy for EB, there have been
significant concerns regarding this ap-
proach. One of them revolves around
the safety of the retroviral vectors used
to integrate the transgene into the
genome, and specifically, the concern
highlights the possibility that random
insertion of the transgene results
in activation of proto-oncogenes or
inactivation of tumor suppressive genes
(De Luca et al., 2009). These concerns
were raised in response to clinical
trials in which introduction of the
curative transgene into hematopoietic
progenitor cells of patients with
X-linked severe combined immuno-
deficiency caused activation of a
T cell proto-oncogene, resulting in
leukemia (Hacein-Bey-Abina et al.,
2003). Although it has been suggested
that, on statistical grounds, the prob-
ability of such an event to occur is
extremely low, and that the retroviral
integration into the genome may not be
random, these concerns have resulted
in the conclusion that the Maloney
leukemia virus long-terminal repeat-
based vectors are not acceptable for
genetic modification of stem cells, and
such clinical trials are now banned by
the regulatory agencies in many coun-
tries in Europe (see De Luca et al.,
2009). Nevertheless, there have been
significant improvements in vector de-
sign, and many of them have poten-
tially a more favorable safety profile
due to targeted integration sites and
self-inactivating properties (Titeux
et al., 2010). On the basis of these
considerations, clinical gene therapy
trials focusing on the recessive dys-
trophic forms of EB have been recently
initiated (Dr. Alfred Lane, Stanford
University, personal communication).
In the context of ex vivo keratino-
cyte gene therapy, the phenomenon
known as revertant mosaicism is of
considerable interest (Lai-Cheong
et al., 2011; Pasmooij and Jonkman,
2012). Revertant mosaicism in skin
diseases was originally noted in a
patient with a junctional form of EB,
where areas of skin were shown to
reacquire the wild-type phenotype
through naturally occurring mitotic
gene conversion (Jonkman et al.,
1997). Thus, revertant mosaicism
reflects ‘‘natural gene therapy,’’ which
could provide corrected, patient-specific
cells for grafting purposes (Gostynski
et al., 2009).
RNA INTERFERENCE TECHNOLOGY
Another gene therapy approach for
treatment of inherited skin diseases
utilizes silencing of the mutant RNA
by short-interfering RNA (siRNA;
Figure 2). Specifically, the safety and
efficacy of a siRNA targeting mutant
keratin 6a (N171K) has been recently
reported in a patient with pachyony-
chia congenita (PC). The Milestone
paper by Leachman et al. (2010)
describes a patient with PC, a disabling
keratinization disorder affecting the
skin, nails, oral mucosa, hair, and
teeth. This disease is inherited in an
autosomal dominant fashion and
often leads to painful lesions in the feet
characterized by blistering and callus
formation on the soles. PC is caused
by mutations in either keratin 6, 16, or
17 genes, and the mutant poly-
peptides cause the clinical manifesta-
tion by dominant-negative interference
(McLean et al., 2011). The approach
of this study was to elicit a selective
depletion of the mutant keratin by
injection of siRNA using a siRNA mole-
cule carefully selected to be mutant-
specific and not interfere with the wild-
type K6a mRNA.
This double-blind study consisted of
injection of the siRNA to one foot while
Ex vivo keratinocyte gene therapy
Figure 1. Strategy for an ex vivo patient-specific keratinocyte gene therapy. Keratinocytes cultured from the patient’s skin biopsy are transduced with
a vector expressing the transgene, and the transgenic cells are selected and grown into epithelial sheets that can be grafted back to the patient (adapted from
Tamai et al., 2009, with permission from Elsevier).
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the other foot received a vehicle–con-
trol solution (Leachman et al., 2010).
The treatment consisted of 17 weeks of
two times weekly injections and was
followed by a 3-month washout. Care-
ful assessment of the clinical signs and
symptoms revealed definitive improve-
ment, and the size of the callus in
siRNA-injected sites was getting smal-
ler. Thus, this first-in-human double-
blinded phase 1b clinical trial sug-
gested the proof-of-principle of RNA
interference technology for patients
with keratinization disorders.
This study also highlighted some of
the drawbacks of this approach. First,
the siRNA was delivered by direct
injection to the lesional skin, resulting
in intense pain (Leachman et al., 2010).
Consequently, significant efforts are
now focusing on improved delivery
methods, such as pharmaceutical
formulations for topical, non-invasive
delivery for PC, and other keratin
disorders (Kaspar et al., 2009; McLean
and Moore, 2011). Another concern is
that although there was a dramatic and
specific response in the treated area of
skin, the improvement appeared to be
temporary, and upon discontinuation
of the treatment, the lesions returned
to their original size. Thus, continuous
treatment by improved topical delivery
system might be required for this
approach (Smith et al., 2008). Finally,
it has been pointed out that one of the
disadvantages of the allele-specific
gene silencing approach is that the US
Food and Drug Administration and
corresponding international agencies
may consider each mutation-specific
siRNA as a separate entity requiring
individual toxicity studies and regula-
tory approval (see Uitto et al., 2012).
Thus, an alternative approach to the
mutant allele–specific ablation, for
example, in case of PC, would be total
silencing of all KRT6A alleles, both
mutant and wild type (Figure 2). It
should be noted that the blistering
phenotype does not occur in the com-
plete absence of K6a because of func-
tional redundancy with K6b and K6c,
allowing normal intermediate filament
network integrity. Clinical trials are
now being contemplated using these
approaches for PC and other keratini-
zation disorders (Dr Irwin McLean,
University of Dundee, personal com-
munication).
ALLOGENEIC FIBROBLAST THERAPY
The Milestone article by Wong et al.
(2008) reported on a clinical trial in
which the potential for intradermal
injections of allogeneic fibroblasts
were assessed in individuals with
recessive dystrophic EB (RDEB). These
studies were based on the premise that
human skin fibroblasts, in addition to
keratinocytes, express type VII collagen
(Stanley et al., 1985; Chen et al., 1994).
Furthermore, previous animal studies
have suggested that COL7A1 gene–
corrected human RDEB fibroblasts
overexpressing type VII collagen, when
injected intradermally into immuno-
deficient mouse skin or into a trans-
planted human RDEB skin xenograft,
allowed sustained human type VII
collagen deposition at the dermal
epidermal junction, accompanied by
anchoring fibril formation (Woodley
et al., 2003). These observations lead
the authors to postulate that injection of
a sufficient number of normal fibro-
blasts could lead to amelioration of the
skin phenotype in patients with RDEB.
Five subjects were injected with
cultured autologous fibroblasts into
the edge of unblistered skin, and the
expression of type VII collagen was
evaluated by immunofluorescence in
biopsies at 2 weeks and 3 months after
a single injection (Wong et al., 2008).
Significant, up to B2-fold increase in
type VII collagen immunostaining was
noted at sites injected with parental
Figure 2. Small interfering RNA (siRNA) strategies for autosomal dominant keratin 6a disorders by targeting either mutant or both mutant and wild-type
alleles. (a) In normal keratinocytes, synthesis of K6a (blue), K6b (red), and K6c (green) occurs; (b) in pachyonychia congenita keratinocytes with a heterozygous
missense mutation in KRT6A, there is a dominant-negative interference between the wild-type and mutant K6a protein that perturbs the entire keratin
network and compromises cell integrity, leading to skin blistering as a result of minor trauma; (c) one siRNA approach is to target the mutant KRT6A allele
to leave only residual wild-type KRT6A allele expression; (d) an alternative siRNA strategy is to silence all KRT6A, both mutant and wild-type—blistering
does not occur in the absence of K6a because of functional redundancy with K6b and K6c, allowing normal intermediate filament network integrity (reproduced
from Uitto et al., 2012).
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fibroblasts or from those of unrelated
donors. The increased type VII collagen
at the dermal–epidermal junction was
accompanied with an increase in an-
choring fibrils, although these were not
fully developed. Nevertheless, this and
complementary studies demonstrated
the potential of allogeneic fibroblast
therapy for treatment of RDEB (Petrova
et al., 2010; Yan and Murrell, 2010).
One of the observations in this
study was that the allogeneic cells, as
determined by Y chromosome positi-
vity in female patients injected with
male fibroblasts, were not detectable
2 weeks after the initial injection, yet
type VII collagen deposition continued
up to 3 months (Wong et al., 2008).
Although initial observations of the
injection sites did not reveal evidence
of significant inflammation, subse-
quent studies suggested a subclinical
immunological mechanism by which
the allogeneic fibroblasts elicit increa-
sed type VII collagen expression in the
basal keratinocytes of the recipient’s
skin (Nagy et al., 2011) (Figure 3).
This conclusion was supported by the
observation that increased type VII
collagen deposition at the dermal–
epidermal junction was particularly
pronounced in those patients who
expressed some type VII collagen at
the baseline, and who, therefore, had
an enhanced capacity to increase
synthesis of their own mutant type VII
collagen. These studies identified
heparin-binding epidermal growth fac-
tor–like growth factor as a novel puta-
tive mediator induced in the recipient
cells by allogeneic fibroblast injection
(Figure 3).
Although these initial studies uti-
lized a single injection of allogeneic
fibroblasts to the skin, the increase in
type VII collagen persisted for several
months. This can be explained, in part,
by the observation that type VII col-
lagen, once deposited to the cutaneous
basement membrane zone, has a rela-
tively long half-life as judged from
mouse studies (Kern et al., 2009).
Clinical trials utilizing multiple injec-
tions at regular intervals are now being
contemplated to counteract the devel-
opment of chronic wounds in patients
with RDEB (Dr John McGrath, St John’s
Institute of Dermatology, personal
communication).
BONE MARROW STEM CELL THERAPY
Cell-based therapy for EB and poten-
tially other heritable skin diseases has
recently been extended to include bone
marrow–derived adult stem cells.
Although these cells are known to have
a critical role in skin homeostasis, it has
also become clear that the plasticity of
these cells enables their differentiation
into cell types responsible for skin
regeneration after injury (Badiavas
et al., 2003; Tamai et al., 2009). The
Milestone article describing the first
clinical trial of allogeneic bone marrow
transplantation for EB was reported by
Wagner et al. (2010). In this study
seven children with severe RDEB were
enrolled to be recipients of bone
marrow transplantation, using standard
myeloablative approach (Wagner et al.,
2010). This study was predicated on
previous animal studies, which have
been conducted to evaluate the poten-
tial of bone marrow–derived stem cells
to treat EB. For example, bone marrow
transfer into the fetal circulation of
mice that are deficient in type VII
collagen resulted in deposition of type
VII collagen in the skin, associated with
reduction in the severity of the blister-
ing in neonatal animals (Chino et al.,
2008). Also, hematopoietic and non-
hematopoetic cell populations were
infused into type VII collagen knockout
mice at birth, and this treatment was
shown to extend the survival of the
recipient mice by several weeks or
months (Tolar et al., 2009). The EB
phenotype was also rescued in a type
XVII collagen knockout model by bone
marrow transplantation (Fujita et al.,
2010). Although type VII collagen is
synthesized both by keratinocytes
and fibroblasts, type XVII collagen,
a component of hemidesmosomes, is
synthesized exclusively by keratino-
cytes. Collectively, these studies
demonstrated that different bone mar-
row–derived stem cells, including me-
senchymal stem cells, can ameliorate
the clinical symptoms and increase the
survival rate of EB mice, thus paving a
way to clinical trials in patients with
different forms of EB.
Bone marrow transplantation in the
children with RDEB was noted to result
in synthesis of new type VII collagen
and clinical improvement that was
sustained for at least 1 year after the
Figure 3. Postulated mechanism by which fibroblast therapy may ameliorate the blistering tendency in recessive dystrophic epidermolysis bullosa (RDEB).
(a) In normal skin, keratinocytes synthesize type VII collagen molecules (red), which assemble into anchoring fibrils. These fibrils entrap the interstitial collagen
fibers in the dermis, securing the stable association at the dermal–epidermal junction. (b) In some patients with RDEB, there are only a few rudimentary
anchoring fibrils, allowing formation of blisters below the lamina densa as a result of minor trauma. (c) Allogeneic fibroblasts injected directly into dermis elicit
a subclinical immune reaction that leads to synthesis of heparin-binding epidermal growth factor–like growth factor (HB–EGF), which upregulates the synthesis
and assembly of patient’s own mutated type VII collagen. The increase in the rudimentary anchoring fibrils, which are partially functional, stabilizes the
association of epidermis to the underlying dermis and ameliorates the blistering tendency (adapted from Uitto, 2011a).
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transplantation (Wagner et al., 2010;
Tolar et al, 2011). Although these
preliminary studies were promising
and generated cautious optimism, it
should be noted that two of the seven
children died as a result of complica-
tions of the bone marrow transplant
procedure, which utilized traditional
chemoablative preconditioning of the
recipients. A second clinical bone
marrow transplantation trial has been
initiated with the approach to use
reduced-intensity chemotherapy before
transplantation, perhaps having lesser
side effects with reduced morbidity and
mortality (Kiuru et al., 2010).
In addition to bone marrow trans-
plantation, a pilot study on two patients
with severe RDEB has tested the
efficacy of intradermal injection of
allogeneic mesenchymal stem cells
into chronic ulcerative sites in these
patients (Conget et al., 2010). Improved
wound healing lasting up to 4 months
was attributed to replenishment of type
VII collagen, which was undetectable
before the procedure. Similar studies
are now being developed to examine
whether intradermal or intravenous
injection of bone marrow–derived
mesenchymal stem cells can improve
the clinical outcome. Collectively,
these early observations support the
usefulness of bone marrow stem cell
populations in the treatment of herita-
ble skin diseases, such as RDEB.
NOVEL THERAPEUTIC APPROACHES
A number of new technologies are
currently being developed for potential
treatment of EB, but these have not
reached the clinical trial stage as yet.
One of such approaches focuses on
induced pluripotent stem cells (iPSCs),
which allow patient-specific cells to be
corrected for the gene defect, followed
by introduction of differentiated fibro-
blast and/or keratinocytes to the skin
(Uitto et al., 2012) (Figure 4). This
approach would circumvent the diffi-
culties in obtaining sufficient numbers
of patient-specific cells and avoid
the problem of immune rejection.
Recently, patient-specific iPSCs have
been generated from several human
diseases to investigate the disease
mechanisms, test potential drugs,
and develop cell-based therapies. In
the case of heritable skin diseases,
patient-specific iPSCs have been gen-
erated from patients with dyskeratosis
congenita as well as RDEB (Agarwal
et al., 2010; Itoh et al., 2011; Tolar
et al., 2011). Although a number of
technological issues still need to be
resolved before iPSC-based therapy can
be moved to the clinic, there is rapid
technological progress in this area, and
the first report of gene correction
utilizing patient-specific iPSCs has
already been published in a case with
gyrate atrophy (Howden et al., 2011),
providing a proof-of-concept for this
technology.
Another approach to counteract the
clinical manifestations of EB, which has
not reached the clinical trial stage yet,
is potential protein-replacement ther-
apy. This concept is again predicated
on the use of Col7a1 knockout mice as
a platform, which demonstrated that
infusion of a purified type VII collagen
results in significantly reduced blister-
ing and extends the lifespan of these
mice (Remington et al., 2009). Again,
once the type VII collagen has been
properly deposited on the cutaneous
basement membrane zone, the protein
remains stably assembled for several
months. Clinical trials utilizing GMP-
purified type VII collagen are currently
contemplated for patients with severe
RDEB (Dr David Woodley, University
of Southern California, personal com-
munication).
Collectively, regenerative medicine
for heritable skin diseases is moving
very rapidly, and with novel techno-
logical innovations the field is making
progress towards treatment and cure of
these, currently intractable disorders.
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